The latest addition to ResearchAndMarkets.com’s offerings is the “Reproductive Hormones and Proteins Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033” report. This insightful analysis delves into the Reproductive Hormones and Proteins Tests Market, projecting trends and…
Aiming to advance treatment options for seizure disorders, Marinus Pharmaceuticals has successfully completed enrollment in the global Phase 3 TrustTSC trial. This trial assesses oral ganaxolone’s efficacy in managing seizures associated with tuberous sclerosis complex (TSC) across various age groups.…
Azitra, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering innovative therapies for precision dermatology, has unveiled preclinical findings from its cutting-edge platform and pipeline. These findings are being presented at the Society of Investigative Dermatology (SID) 2024 Annual Meeting in…
The World Health Organization (WHO) has unveiled its updated Bacterial Priority Pathogens List (BPPL) for 2024, highlighting 15 families of antibiotic-resistant bacteria grouped into critical, high, and medium categories for prioritization. This list serves as a compass for the development…
A spatial AI biomarker company specializing in deciphering cellular conversations and mapping cellular interactions within tissue samples to predict therapeutic outcomes has announced the expansion of its executive leadership team. Nucleai revealed today the appointment of Vikas Ahuja as Vice…
Accenture Ventures, a strategic arm of Accenture (NYSE: ACN), recently announced its investment in Turbine, a forward-thinking predictive simulation company dedicated to interpreting human biology. This investment aims to bolster Turbine’s capabilities in providing valuable biological insights to global biopharma…
Genentech, a member of the Roche Group, disclosed favorable outcomes from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist aimed at addressing obesity and type 2 diabetes. The study revealed that administering CT-388 through a once-weekly…
Nutcracker Therapeutics, a biotechnology company focused on developing transformative RNA therapies through its proprietary technology platform, announced the presentation of key prostate cancer antigen research by its partners at the University of California, San Francisco (UCSF). The data, foundational to…
Legend Biotech Corporation (NASDAQ: LEGN), a global pioneer in cell therapy, unveiled its unaudited financial performance for the first quarter of 2024 alongside notable corporate achievements. Dr. Ying Huang, CEO of Legend Biotech, expressed satisfaction with the progress made during…
UCB, a global biopharmaceutical company, announced that the Journal of Neurology has published data from the Phase 3 RAISE study and the ongoing RAISE-XT open-label extension (OLE) study on the long-term effects of zilucoplan on fatigue in adult patients with…
Sanofi, the largest private contributor to France’s health ecosystem security and independence, announced a €1 billion investment to expand bioproduction at its sites in Vitry-sur-Seine, Le Trait, and Lyon Gerland. This initiative will create over 500 jobs, enhancing France’s capacity…
AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals have announced a collaboration and option-to-license agreement aimed at developing next-generation therapies for psychiatric disorders. This partnership combines AbbVie’s psychiatric expertise with Gilgamesh’s innovative research platform to discover novel neuroplastogens. Classic psychedelic compounds offer…